VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

General Updates | Identifying novel antigens for TCR T-cell therapy

David Apelian, MD, PhD, BlueSphere Bio, Pittsburgh, PA, discusses work he is involved with on the first minor histocompatibility antigen (miHA) platform to treat patients with high-risk leukemia undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). In addition, work is being done to identify novel shared antigens that can be targeted by T-cell receptor (TCR) T-cells before achieving a fully personalized treatment platform to treat patients. This interview was recorded virtually.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter